236426 Community-based addiction treatment clinical trials: Site variation

Tuesday, November 1, 2011: 2:30 PM

Dennis McCarty, PhD , Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR
Allie Buti, MPH , Public Health & Preventive Medicine, Oregon Health & Science University, Portland, OR
Lynn Kunkel, MS, CCRP , Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR
Holly Fussell, PhD , Department of Public Health & Preventive Medicine, Oregon Health & Science University, Portland, OR
Danielle Eakins, BA , Department of Public Health & Preventive Medicine, Oregon Health & Science University, Portland, OR
Michele Straus, RPh, MS , Center for Clincal Trials Network, National Institute on Drug Abuse, Bethesda, MD
The National Drug Abuse Treatment Clinical Trials Network (CTN) conducts multi-site clinical trials in community-based drug abuse treatment centers to test the effectiveness and generalizability of emerging pharmacological and behavioral therapies for drug addiction. Site differences are common in multi-site trials but the sources of the variation are unclear. A trial of interventions to reduce HIV risk behaviors, for example, found that a site characteristic (distance between a detoxification center and an outpatient center) was the strongest predictor of entering outpatient care following detoxification. To begin to address site variation, the CTN collects workforce and organizational data at participating sites prior to implementing new trials. Data from four trials suggest that sites varied prior to trial implementation on staff composition (e.g., % counselors with graduate degrees, % counselors in recovery), and clinical director commitment to implementation. Sites also vary on how the protocol is organized and implemented within each treatment center. Clinical directors were more committed to protocol implementation than counselors. Counselors were more committed to implementation of a twelve-step facilitation protocol than to a smoking cessation protocol. Variation was apparent both within and across trials. The variation may affect protocol implementation and influence client outcomes. Future analyses will link site data with patient outcomes. It is essential to begin to understand the sources of site variation in outcomes.

Learning Areas:
Conduct evaluation related to programs, research, and other areas of practice
Public health or related public policy

Learning Objectives:
Describe the addiction treatment programs participating in the National Drug Abuse Treatment Clinical Trials Network (CTN). Evaluate the influence of site characteristics on protocol implementation and patient outcomes.

Keywords: Alcohol Problems, Drug Abuse Treatment

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am a member of APHA and a Principle Investigator in the CTN
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.